Prevalence of Severe Asthma in Spanish Hospitals

Sponsor

GlaxoSmithKline (Industry)

Overall Status

Completed

CT.gov ID

NCT03137043

Collaborator

Quintiles IMS (Other)

356

Enrollment

Locations

30.3

Actual Duration (Months)

10.8

Patients Per Site

0.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Asthma is a chronic disease. Prevalence of asthma in 2014 among Spanish population was 5%, of which 10% were diagnosed with severe asthma. According to Spanish National Guideline for the Management of Asthma (GEMA) 4.1 criteria, asthma can be classified according to its severity (intermittent, mild persistent, moderate persistent or severe persistent) or level of asthma control (controlled, partly controlled or uncontrolled). This Guideline describes that only 1 in 10 subjects with severe asthma is well controlled, meaning that there is a 90% prevalence of non-controlled severe asthma.

This prospective, non-interventional, observational, multicenter and case-control study aims to assess the prevalence of severe asthma in Spanish Hospitals. The study will describe the characteristics of severe versus non-severe asthmatic subjects, assess their eligibility to receive biological treatments approved for this disease, resource consumption and evaluate the most prevalent phenotypes of severe asthma in Spain. Enrolled subjects will be divided into two cohorts, based on asthma severity according to the Global Initiative for Asthma (GINA) and the International European Respiratory Society (ERS)/American Thoracic Society (ATS) Guidelines. Cohort A: subjects diagnosed of severe asthma and Cohort B: subjects with non-severe asthma. Approximately 320 severe asthmatic subjects and 160 non-severe asthmatic subjects will be enrolled in the study. A software of big data will be used to do a sub study for comparing the results obtained through this software tool against results obtained through Gold standard classical methods used in this prospective observational study (the descriptive assessment of severe asthma prevalence and the prospective evolution of subjects).

Condition or Disease	Intervention/Treatment	Phase
Asthma	Other: Questionnaire Other: Software of Big Data

Study Design

Study Type:

Observational

Actual Enrollment :

356 participants

Observational Model:

Case-Control

Time Perspective:

Prospective

Official Title:

Observational Study to Describe the Prevalence of Severe Asthma in Spanish Hospitals

Actual Study Start Date :

Nov 22, 2017

Actual Primary Completion Date :

Jun 2, 2020

Actual Study Completion Date :

Jun 2, 2020

Arms and Interventions

Arm	Intervention/Treatment
Severe Asthmatic Subjects Subjects requiring high dose inhaled corticosteroids (ICS) plus a second controller (and/or systemic glucocorticosteroids) to prevent it from becoming 'uncontrolled' or which remains 'uncontrolled' despite the therapy.	Other: Questionnaire Subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Asthma Control Test, Morisky-Green Questionnaire and St George's Respiratory Questionnaire. Other: Software of Big Data Software of big data is a powerful data treatment algorithm works closely with Spanish Data Protection Agency as an example on how to reuse clinical information without conflicting with necessary data privacy. The system will process a vast amount of information (big data), so that the impact of random errors will be minimized.
Non-Severe Asthmatic Subjects Subjects with intermittent, persistent mild or moderate asthma.	Other: Questionnaire Subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Asthma Control Test, Morisky-Green Questionnaire and St George's Respiratory Questionnaire. Other: Software of Big Data Software of big data is a powerful data treatment algorithm works closely with Spanish Data Protection Agency as an example on how to reuse clinical information without conflicting with necessary data privacy. The system will process a vast amount of information (big data), so that the impact of random errors will be minimized.

Arm

Intervention/Treatment

Severe Asthmatic Subjects

Subjects requiring high dose inhaled corticosteroids (ICS) plus a second controller (and/or systemic glucocorticosteroids) to prevent it from becoming 'uncontrolled' or which remains 'uncontrolled' despite the therapy.

Other: Questionnaire

Subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Asthma Control Test, Morisky-Green Questionnaire and St George's Respiratory Questionnaire.

Other: Software of Big Data

Software of big data is a powerful data treatment algorithm works closely with Spanish Data Protection Agency as an example on how to reuse clinical information without conflicting with necessary data privacy. The system will process a vast amount of information (big data), so that the impact of random errors will be minimized.

Non-Severe Asthmatic Subjects

Subjects with intermittent, persistent mild or moderate asthma.

Other: Questionnaire

Subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Asthma Control Test, Morisky-Green Questionnaire and St George's Respiratory Questionnaire.

Other: Software of Big Data

Outcome Measures

Primary Outcome Measures

To estimate the prevalence of severe asthmatic subjects at Spanish sites [Up to 12 months]
Assessment will be done based on the type of hospital, department type of hospital or clinic, sources of the service and number of asthmatic subjects diagnosed according to GEMA guidelines.

Secondary Outcome Measures

Number of subjects with sociodemographic characteristics of severe asthmatic subjects compared to non-severe asthmatic subjects [Up to 12 months]
Subjects with different age, gender, ethnicity, education, occupational status, marital status, physical examination, smoking status, family history, co-morbidities and allergies will be compared for descriptive analysis of sociodemographic characteristics of subjects with severe asthma and non-severe asthma participating in this study.
Number of subjects with clinical characteristics of severe asthmatic subjects compared to non-severe asthmatic subjects [Up to 12 months]
Subjects with asthma severity, age of asthma onset, laboratory tests, biomarkers, skin prick test, airflow tests, asthma symptoms and exacerbations will be compared for clinical characteristics analysis of subjects with severe asthma and non-severe asthma participating in this study.
To estimate the prevalence of different phenotypes in severe asthma [Up to 12 months]
Prevalence of different severe asthma phenotypes (allergic, base on prick test, Immunoglobulin E (IgE), eosinophilic, based on eosinophils counts >= 300 cells/millimeter cubed in blood samples in the previous year, obesity, based on the absence of positive prick test, IgE or high eosinophils counts in blood sample; neutrophilic, just in case eosinophils in sputum are available.
Number of subjects who comply with eligibility criteria to receive biological treatment for severe asthma [Up to 12 months]
Number of exacerbations; Oral Corticosteroid (OCS) treatment; Number of visits to emergency room (ER) and/or hospitalization within the last 12 months, sputum eosinophils (if done), eosinophils in blood, IgE (specific and total), forced expiratory volume-one second (FEV1), Asthma Control Test (ACT), percentage of reversibility will be assessed.
Number of subjects evolved with severe asthma and non-severe asthma at 6 and 12 months from baseline [Up to 12 months]
Exacerbations; visits to emergency room; changes in treatment or dose increase, add-on therapy addition, Disease control (3-score change in ACT), Disease control state (uncontrolled, partially controlled, well controlled) according to guidelines, Quality of life (4-score change in SGRQ), mortality will be assessed.
Number of subjects evolved with severe asthma in comparison with non severe asthma at 6 and 12 months [Up to 12 months]
Subjects with severe and non severe asthma at 6 and 12 months will be compared.
To assess the social impact of subjects with severe asthma in comparison with non-severe asthmatic subjects in terms of Health Related Quality of Life (HRQoL) [Up to 12 months]
Health Related Quality of Life (HRQoL) will be analyzed from the SGRQ Questionnaire scores. Scores will be expressed as percentage of overall impairment, where 100 represents worst possible health and 0 indicates best possible health status.
To assess the use of healthcare resources (direct and indirect) in subjects with severe asthma and non-severe asthma [Up to 12 months]
Direct resources will include number of inpatient admissions, emergency and hospitalized visits, tests to be conducted, etc. on patients with severe asthma. The medical resources used (tests, admissions, etc.) will be analyzed descriptively during the observation period. The direct cost will be calculated by taking into account the resources used and unit costs at a local level. Indirect resources will include reduced productivity of patients with severe asthma through an ad-hoc questions like total number of work days lost due to asthma in the last 6 months.
To predict evolution of subjects with severe and non-severe asthma at month 6 and month 12, based on the physician's experience and knowledge, compared to results obtained through monitoring [Up to 12 months]
The variables to be predicted will be exacerbations; visits to ER; changes in treatment or dose increase; add-on therapy addition; disease control (3-score change in ACT); disease control state (uncontrolled, partially controlled, well controlled) according to guidelines, Quality of life (4-score change in SGRQ) and mortality will be assessed.
To establish the determinant factors clinicians use, to predict subjects evolution [Up to 12 months]
FEV1 (pre & post), percentage reversibility FEV1, number of exacerbations, use of rescue medication, changes to the treatment required, need for adding a biological treatment, concomitant diseases or comorbidities, asthma symptoms; tobacco, eosinophils in blood or sputum, Asthma Control measured by ACT, number or hospitalizations; number of emergency department visits; dose of inhaled glucocorticosteroids, need and dose of oral glucocortocosteroids, mortality, adherence to medication, inhaler technique, fractionated exhaled nitric oxide level (FeNO), Body Mass Index (BMI), GINA treatment Step, living in a rural environment, chronic obstructive pulmonary disease (COPD), male sex, black race, lower educational level will be the determining factor for clinicians.
To test if the calculated prevalence using a specific software is similar to the prevalence of severe asthma obtained through monitoring using gold standard [Up to 12 months]
This will provide a descriptive comparison between the gold standard data and the software's prediction.
To compare the prediction in the evolution of subjects with severe asthma at 6 and 12 months, based on the aggregated information collected in the last 5 years previous to the start of the observational study with the prediction done by the physician [Up to 12 months]
This will provide a descriptive comparison between the clinician's prediction and the software's prediction.
To compare the software's prediction in the evolution of subjects with severe asthma at 6 and 12 months with the results obtained by monitoring in the observational study [Up to 12 months]
Gold standard data collected by monitoring will be compared against the real data.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria

Group A: Subjects with Severe asthma can be enrolled, when they fulfill the following criteria:
Subjects >= 18 years
Subjects diagnosed with "severe asthma" defined as asthma that requires high-dose inhaled corticosteroids (ICS) plus Long-Acting Beta2-Agonist (LABA), leukotriene modifier/ theophylline in the last 12 months or continuous/almost continuous treatment with systemic glucocorticosteroids (CS) for >= 50% of the previous year to maintain control of asthma
Subjects treated with ICS/LABA, with the maximum dose recommended by Specific Product Characteristics (SPC).
Subjects who give voluntary written informed consent after explanation of study´s procedures.
Group B: Subjects with Non-Severe asthma can be enrolled, when they fulfill the following criteria:
Subjects >= 18 years
Subjects diagnosed with non-severe asthma per GINA Guidelines Classification
Subjects who give voluntary written informed consent after explanation of study´s procedures

Exclusion Criteria

Subjects who are not able to complete all the follow-ups of the study with all the study procedures

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	GSK Investigational Site	Laredo	Cantabria	Spain	39770
2	GSK Investigational Site	Badalona		Spain	08916
3	GSK Investigational Site	Barcelona		Spain	08035
4	GSK Investigational Site	Cartagena (Murcia)		Spain	30202
5	GSK Investigational Site	Cáceres		Spain	10003
6	GSK Investigational Site	Elda (Alicante)		Spain	03600
7	GSK Investigational Site	L'Hospitalet de Llobregat		Spain	08907
8	GSK Investigational Site	La Coruña		Spain	15006
9	GSK Investigational Site	La Laguna-Tenerife		Spain	38320
10	GSK Investigational Site	Loja/ Granada		Spain	18300
11	GSK Investigational Site	Lérida		Spain	25198
12	GSK Investigational Site	Madrid		Spain	28006
13	GSK Investigational Site	Madrid		Spain	28007
14	GSK Investigational Site	Madrid		Spain	28031
15	GSK Investigational Site	Madrid		Spain	28034
16	GSK Investigational Site	Madrid		Spain	28040
17	GSK Investigational Site	Madrid		Spain	28041
18	GSK Investigational Site	Majadahonda (Madrid)		Spain	28222
19	GSK Investigational Site	Marbella		Spain	29600
20	GSK Investigational Site	Murcia (El Palmar)		Spain	30120
21	GSK Investigational Site	Pamplona		Spain	31008
22	GSK Investigational Site	Ponferrada (León)		Spain	24411
23	GSK Investigational Site	Sagunto/Valencia		Spain	46520
24	GSK Investigational Site	Salamanca		Spain	37007
25	GSK Investigational Site	Santiago de Compostela		Spain	15706
26	GSK Investigational Site	Sevilla		Spain	41013
27	GSK Investigational Site	Sevilla		Spain	41071
28	GSK Investigational Site	Valdemoro/Madrid		Spain	28340
29	GSK Investigational Site	Valencia		Spain	46017
30	GSK Investigational Site	Valencia		Spain	46026
31	GSK Investigational Site	Xátiva-Valencia		Spain	46800
32	GSK Investigational Site	Zaragoza		Spain	50009
33	GSK Investigational Site	Zaragoza		Spain	50015